Publicaciones científicas
EUSOMA quality indicators for non-metastatic breast cancer: An update
Isabel T Rubio 1 , Lorenza Marotti 2 , Laura Biganzoli 3 , Cynthia Aristei 4 , Alexandra Athanasiou 5 , Christine Campbell 6 , Fatima Cardoso 7 , Maria Joao Cardoso 8 , Charlotte E Coles 9 , Manuela Eicher 10 , Nadia Harbeck 11 , Andreas Karakatsanis 12 , Birgitte V Offersen 13 , Ruud Pijnappel 14 , Antonio Ponti 15 , Peter Regitnig 16 , Donatella Santini 17 , Francesco Sardanelli 18 , Tanja Spanic 19 , Zsuzsanna Varga 20 , Marie Jeanne T F D Vrancken Peeters 21 , Yvonne Wengström 22 , Lynda Wyld 23 , Giuseppe Curigliano 24
Introduction: Quality care in breast cancer is higher if patients are treated in a Breast Center with a dedicated and specialized multidisciplinary team. Quality control is an essential activity to ensure quality care, which has to be based on the monitoring of specific quality indicators. Eusoma has proceeded with the up-dating of the 2017 Quality indicators for non-metastatic breast cancer based on the new diagnostic, locoregional and systemic treatment modalities.
Methods: To proceed with the updating, EUSOMA setup a multidisciplinary working group of BC experts and patients' representatives. It is a comprehensive set of QIs for early breast cancer care, which are classified as mandatory, recommended, or observational. For the first time patient reported outcomes (PROMs) have been included. As used in the 2017 EUSOMA QIs, evidence levels were based on the short version of the US Agency for Healthcare Research and Quality.
Results: This is a set of quality indicators representative for the different steps of the patient pathway in non-metastatic setting, which allow Breast Centres to monitor their performance with referring standards, i.e minimum standard and target.
Conclusions: Monitoring these Quality Indicators, within the Eusoma datacentre will allow to have a state of the art picture at European Breast Centres level and the development of challenging research projects.
CITA DEL ARTÍCULO Eur J Cancer. 2023 Dec 26:198:113500. doi: 10.1016/j.ejca.2023.113500
Nuestros autores
